The study aimed to develop a blood-based biomarker panel that can predict the development of Parkinson's disease (PD) years before the onset of clinical symptoms. The researchers performed a proteomics analysis of plasma samples from patients with de novo PD and healthy controls, identifying 23 dysregulated proteins involved in inflammatory pathways, Wnt-signaling, and coagulation cascade.
They then constructed a targeted mass spectrometry proteomic assay with 121 proteins and applied it to additional samples, including those from patients with other neurological diseases and isolated REM sleep behavior disorder (iRBD). This led to the identification of a panel of 8 proteins (GRN, MASP2, HSPA5, PTGDS, ICAM1, complement C3, DKK3, and SERPING1) that could accurately identify PD patients and predict with 79% accuracy which iRBD patients would convert to PD up to 7 years before motor symptom onset.
The biomarker panel was also found to correlate with clinical scores on the Unified Parkinson's Disease Rating Scale and Mini-Mental State Examination. The researchers plan to validate the findings in a larger cohort and note that the ability to identify early PD could aid in recruitment for preventative clinical trials and potentially lead to new treatment options targeting the dysregulated pathways.
To Another Language
from source content
www.medscape.com
Ключові висновки, отримані з
by Patrice Wend... о www.medscape.com 06-18-2024
https://www.medscape.com/viewarticle/blood-biomarker-panel-may-predict-parkinsons-years-advance-2024a1000bckГлибші Запити